Citizens Financial Group Inc RI reduced its position in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 46.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 727 shares of the medical technology company’s stock after selling 631 shares during the period. Citizens Financial Group Inc RI’s holdings in Hill-Rom were worth $73,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in HRC. Amundi Pioneer Asset Management Inc. lifted its position in shares of Hill-Rom by 3.4% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 132,190 shares of the medical technology company’s stock worth $13,993,000 after purchasing an additional 4,312 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Hill-Rom by 4.8% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,508 shares of the medical technology company’s stock worth $512,000 after purchasing an additional 208 shares during the last quarter. Strategic Investment Advisors MI purchased a new stake in shares of Hill-Rom during the 4th quarter worth $226,000. State of Michigan Retirement System lifted its position in shares of Hill-Rom by 1.6% during the 4th quarter. State of Michigan Retirement System now owns 19,650 shares of the medical technology company’s stock worth $2,231,000 after purchasing an additional 300 shares during the last quarter. Finally, Transform Wealth LLC purchased a new stake in shares of Hill-Rom during the 4th quarter worth $246,000. 85.90% of the stock is owned by institutional investors and hedge funds.
Shares of HRC opened at $99.08 on Friday. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.52 and a quick ratio of 1.22. The stock has a market cap of $6.59 billion, a PE ratio of 45.45, a price-to-earnings-growth ratio of 1.16 and a beta of 0.75. Hill-Rom Holdings, Inc. has a 1-year low of $72.29 and a 1-year high of $117.50. The firm has a fifty day moving average price of $107.38 and a 200 day moving average price of $105.97.
Hill-Rom (NYSE:HRC) last posted its quarterly earnings data on Friday, May 1st. The medical technology company reported $1.28 EPS for the quarter, beating analysts’ consensus estimates of $1.15 by $0.13. The company had revenue of $723.20 million for the quarter, compared to analyst estimates of $701.72 million. Hill-Rom had a net margin of 5.04% and a return on equity of 22.60%. Hill-Rom’s quarterly revenue was up 1.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.14 earnings per share. As a group, equities analysts expect that Hill-Rom Holdings, Inc. will post 5.47 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Friday, June 19th will be paid a $0.22 dividend. The ex-dividend date is Thursday, June 18th. This represents a $0.88 dividend on an annualized basis and a yield of 0.89%. Hill-Rom’s dividend payout ratio is presently 17.32%.
HRC has been the subject of several recent analyst reports. Morgan Stanley decreased their price objective on shares of Hill-Rom from $138.00 to $125.00 and set an “overweight” rating for the company in a research report on Friday, March 27th. UBS Group reduced their price target on shares of Hill-Rom from $130.00 to $125.00 and set a “buy” rating for the company in a research report on Monday, May 4th. Barclays reissued a “buy” rating and issued a $125.00 price target on shares of Hill-Rom in a research report on Tuesday, April 14th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $131.00 price target on shares of Hill-Rom in a research report on Friday, January 24th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $122.33.
In other Hill-Rom news, insider Amy M. Dodrill sold 3,189 shares of Hill-Rom stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $110.00, for a total value of $350,790.00. Following the transaction, the insider now directly owns 1,389 shares in the company, valued at $152,790. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 0.65% of the company’s stock.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Further Reading: Diversification Important in Investing
Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.